Welcome to Markets Desk, your midday read on what's moving and why.
Alphabet is under pressure after reports surfaced that Gemini three point five Pro, the company's most powerful AI model, is facing delays in its broader rollout. The stock slid as investors weighed whether Google is losing ground in the AI race, particularly as competitors push aggressively to market.
Staying in the AI space, Beijing is making its ambitions structural. Xi Jinping has spearheaded a new governmental body designed to extend China's influence over international AI standard-setting, a move that signals Beijing wants to shape the rules of the technology globally, not just compete within them. This is as much a geopolitical story as a market one.
In biotech, there were several meaningful moves worth noting. CareDx surged after Medicare finalized coverage policy for molecular testing related to organ rejection, a significant reimbursement catalyst. AtaiBeckley agreed to be acquired by Eli Lilly, adding another deal to what has been an active stretch for large pharma consolidation. And Abbott lifted its outlook, giving the broader sector a constructive tone heading into the weekend.
That's the tape. Markets Desk, signing off the floor.
